These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31432461)

  • 1. Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients.
    Borgå O; Lilienberg E; Bjermo H; Hansson F; Heldring N; Dediu R
    Adv Ther; 2019 Oct; 36(10):2825-2837. PubMed ID: 31432461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of paclitaxel protein-bound particles in patients with breast cancer: determining total and unbound paclitaxel in plasma by rapid equilibrium dialysis and liquid chromatography-tandem mass spectrometry.
    Li J; Li W; Dai X; Zhong D; Ding Y; Chen X
    Drug Des Devel Ther; 2019; 13():1739-1749. PubMed ID: 31190752
    [No Abstract]   [Full Text] [Related]  

  • 3. Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study.
    Borgå O; Henriksson R; Bjermo H; Lilienberg E; Heldring N; Loman N
    Adv Ther; 2019 May; 36(5):1150-1163. PubMed ID: 30879251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Gardner ER; Dahut WL; Scripture CD; Jones J; Aragon-Ching JB; Desai N; Hawkins MJ; Sparreboom A; Figg WD
    Clin Cancer Res; 2008 Jul; 14(13):4200-5. PubMed ID: 18594000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer.
    Yang D; Xu G; Ding H; Zhong L; Zhu J; Mi X; Xin W; Zhou T; Wang J; Fang L
    Cancer Chemother Pharmacol; 2024 Oct; 94(4):523-534. PubMed ID: 39080018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin-bound paclitaxel: a next-generation taxane.
    Gradishar WJ
    Expert Opin Pharmacother; 2006 Jun; 7(8):1041-53. PubMed ID: 16722814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
    Bulitta JB; Zhao P; Arnold RD; Kessler DR; Daifuku R; Pratt J; Luciano G; Hanauske AR; Gelderblom H; Awada A; Jusko WJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1049-63. PubMed ID: 18791718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
    Ando M; Yonemori K; Katsumata N; Shimizu C; Hirata T; Yamamoto H; Hashimoto K; Yunokawa M; Tamura K; Fujiwara Y
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):457-65. PubMed ID: 21853310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
    Biakhov MY; Kononova GV; Iglesias J; Desai N; Bhar P; Schmid AN; Loibl S
    Expert Opin Drug Saf; 2010 Jul; 9(4):515-23. PubMed ID: 20500029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.
    Stage TB; Bergmann TK; Kroetz DL
    Clin Pharmacokinet; 2018 Jan; 57(1):7-19. PubMed ID: 28612269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study.
    Jain MM; Gupte SU; Patil SG; Pathak AB; Deshmukh CD; Bhatt N; Haritha C; Govind Babu K; Bondarde SA; Digumarti R; Bajpai J; Kumar R; Bakshi AV; Bhattacharya GS; Patil P; Subramanian S; Vaid AK; Desai CJ; Khopade A; Chimote G; Bapsy PP; Bhowmik S
    Breast Cancer Res Treat; 2016 Feb; 156(1):125-34. PubMed ID: 26941199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
    Yamamoto S; Maeda N; Nagashima Y; Kubo H; Sato Y; Matsui H; Inoue Y; Shindo Y; Kanekiyo S; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yoshino S; Hazama S; Oka M; Nagano H
    Breast Cancer; 2017 Nov; 24(6):783-789. PubMed ID: 28439763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases.
    Siqing F; Culotta KS; Falchook GS; Hong DS; Myers AL; Zhang YP; Naing A; Janku F; Hou MM; Kurzrock R
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):357-64. PubMed ID: 26698868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.
    Chen N; Li Y; Ye Y; Palmisano M; Chopra R; Zhou S
    J Clin Pharmacol; 2014 Oct; 54(10):1097-107. PubMed ID: 24719309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Nanoformulations Alter the Tissue Distribution of Paclitaxel, Which Aligns with Reported Distinct Efficacy and Safety Profiles.
    Li F; Zhang H; He M; Liao J; Chen N; Li Y; Zhou S; Palmisano M; Yu A; Pai MP; Yuan H; Sun D
    Mol Pharm; 2018 Oct; 15(10):4505-4516. PubMed ID: 30180593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice.
    Neesse A; Frese KK; Chan DS; Bapiro TE; Howat WJ; Richards FM; Ellenrieder V; Jodrell DI; Tuveson DA
    Gut; 2014 Jun; 63(6):974-83. PubMed ID: 24067278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
    Slingerland M; Guchelaar HJ; Rosing H; Scheulen ME; van Warmerdam LJ; Beijnen JH; Gelderblom H
    Clin Ther; 2013 Dec; 35(12):1946-54. PubMed ID: 24290734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
    Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.